AI's 'Show-Me' Reckoning: Earnings Divergence, Executive Exodus, and Regulatory Tightening
Investors are shifting from rewarding AI narratives to demanding tangible results, evidenced by Adobe's weak guidance despite user-growth emphasis, Palantir's stock decline even after winning the Army's TITAN contract, and UiPath's contrasting guidance raise. Simultaneously, high-profile safety-driven departures from Anthropic and Google, plus new regulatory actions (California's under-16 social media ban, Anthropic's misuse-blocking disclosures), signal mounting scrutiny of AI's societal and financial risk profile even as fintech-adjacent funding (Socure) continues.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
